CY1117437T1 - Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων - Google Patents
Αντισωματα αντι-μεσοθηλινης και χρησεις αυτωνInfo
- Publication number
- CY1117437T1 CY1117437T1 CY20161100353T CY161100353T CY1117437T1 CY 1117437 T1 CY1117437 T1 CY 1117437T1 CY 20161100353 T CY20161100353 T CY 20161100353T CY 161100353 T CY161100353 T CY 161100353T CY 1117437 T1 CY1117437 T1 CY 1117437T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- tumors
- binding domains
- mesothelin
- antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 108090000015 Mesothelin Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102000003735 Mesothelin Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| EP08855189.0A EP2215121B1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117437T1 true CY1117437T1 (el) | 2017-04-26 |
Family
ID=40351874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100353T CY1117437T1 (el) | 2007-11-26 | 2016-04-27 | Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (enExample) |
| EP (3) | EP3103814A1 (enExample) |
| JP (3) | JP5608091B2 (enExample) |
| KR (1) | KR101559599B1 (enExample) |
| CN (2) | CN104151429B (enExample) |
| AU (1) | AU2008329221B2 (enExample) |
| BR (1) | BRPI0819909B8 (enExample) |
| CA (1) | CA2706529C (enExample) |
| CO (1) | CO6280409A2 (enExample) |
| CR (1) | CR11456A (enExample) |
| CU (1) | CU23833A3 (enExample) |
| CY (1) | CY1117437T1 (enExample) |
| DK (1) | DK2215121T3 (enExample) |
| DO (1) | DOP2010000150A (enExample) |
| EC (1) | ECSP10010191A (enExample) |
| ES (1) | ES2569513T3 (enExample) |
| GT (1) | GT201000148A (enExample) |
| HN (1) | HN2010001062A (enExample) |
| HR (1) | HRP20160485T1 (enExample) |
| HU (1) | HUE027358T2 (enExample) |
| IL (1) | IL205681A0 (enExample) |
| MA (1) | MA31862B1 (enExample) |
| MX (1) | MX2010005603A (enExample) |
| MY (1) | MY157164A (enExample) |
| NZ (1) | NZ585551A (enExample) |
| PL (1) | PL2215121T3 (enExample) |
| SI (1) | SI2215121T1 (enExample) |
| TN (1) | TN2010000234A1 (enExample) |
| UA (1) | UA106036C2 (enExample) |
| WO (1) | WO2009068204A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101554753B1 (ko) * | 2007-10-01 | 2015-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
| CN104151429B (zh) * | 2007-11-26 | 2018-07-10 | 拜耳知识产权有限责任公司 | 抗-间皮素抗体及其用途 |
| UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| UA115641C2 (uk) | 2010-12-20 | 2017-11-27 | Дженентек, Інк. | Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| TWI582112B (zh) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二） |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2013324049B2 (en) * | 2012-09-27 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| NZ729808A (en) | 2014-09-30 | 2022-02-25 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| WO2017004254A1 (en) * | 2015-06-30 | 2017-01-05 | Wei-Dong Jiang | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies |
| HK1251948A1 (en) * | 2015-08-21 | 2019-05-03 | 克莱格医学有限公司 | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| US12123876B2 (en) | 2016-02-15 | 2024-10-22 | Kanagawa Prefectural Hospital Organization | Antibody binding to HEG1 and use of the antibody for detection and treatment of mesothelioma |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| SI3443096T1 (sl) | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
| CA3025345A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| SG11201900885VA (en) | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| CN111741976B (zh) | 2017-12-19 | 2024-09-17 | 英沃克斯制药有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
| EA202091488A1 (ru) * | 2017-12-24 | 2020-09-23 | Нойл-Иммьюн Байотек, Инк. | Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19 |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| JP2021521896A (ja) | 2018-04-27 | 2021-08-30 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ヒト由来の抗（ポリｇａ）ジペプチドリピート（ｄｐｒ）抗体 |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| CN112423845B (zh) | 2018-07-12 | 2024-07-30 | F-星治疗有限公司 | 结合pd-l1和cd137的抗体分子 |
| CA3106048A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| US20210253666A1 (en) | 2018-08-30 | 2021-08-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7617012B2 (ja) * | 2019-03-14 | 2025-01-17 | モルフォシス・アーゲー | Ｃ５ａＲを標的とする抗体 |
| KR20220012839A (ko) | 2019-03-19 | 2022-02-04 | 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 | Omomyc와 pd-1 또는 ctla-4에 결합하는 항체를 이용한 암 치료용 조합 요법 |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| WO2021021825A1 (en) * | 2019-07-29 | 2021-02-04 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| US11926672B2 (en) | 2019-12-20 | 2024-03-12 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN116063527A (zh) * | 2021-09-30 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向间皮素的抗体及其用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| JP2025529210A (ja) | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| KR20250089547A (ko) | 2022-10-25 | 2025-06-18 | 펩토믹, 에스.엘. | 암 치료를 위한 조합 요법 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| CN120826416A (zh) * | 2022-12-02 | 2025-10-21 | 杰科生物医药公司 | 抗间皮素双特异性抗体及其使用方法 |
| CN121038806A (zh) | 2023-04-25 | 2025-11-28 | 阿森纳生物科学公司 | 用于转录调控的新颖受体 |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| TW202513088A (zh) | 2023-06-07 | 2025-04-01 | 瓦爾希伯倫私人腫瘤研究基金會 | 用於治療癌症的與ｍｅｋ抑制劑的組合療法 |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| CA2241604C (en) | 1996-01-05 | 2010-03-30 | Ira Pastan | Mesothelium antigen and methods and kits for targeting it |
| CA2318576C (en) | 1997-12-01 | 2009-04-14 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| ES2269105T3 (es) * | 1999-02-26 | 2007-04-01 | Pacific Northwest Research Institute | Metodos y composiciones para el diagnostico de carcinomas. |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| ES2429340T3 (es) * | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
| EP1885758A2 (en) * | 2005-05-12 | 2008-02-13 | The Government of the United States of America as Represented by The Department of Health and Human Services | Anti-mesothelin antibodies useful for immunological assays |
| BRPI0610796B8 (pt) | 2005-05-18 | 2021-05-25 | Morphosys Ag | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo |
| US20110129412A1 (en) * | 2005-06-02 | 2011-06-02 | Astrazeneca Ab | Antibodies Directed to CD20 and Uses Thereof |
| KR101554753B1 (ko) * | 2007-10-01 | 2015-09-22 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
| CN104151429B (zh) * | 2007-11-26 | 2018-07-10 | 拜耳知识产权有限责任公司 | 抗-间皮素抗体及其用途 |
-
2008
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh not_active Expired - Fee Related
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en not_active Ceased
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja not_active Expired - Fee Related
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt not_active IP Right Cessation
- 2008-11-19 HR HRP20160485TT patent/HRP20160485T1/hr unknown
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en not_active Ceased
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko not_active Expired - Fee Related
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en not_active IP Right Cessation
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh not_active Expired - Fee Related
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117437T1 (el) | Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων | |
| CY1119051T1 (el) | Αντισωματα anti-c4.4a και χρησεις αυτων | |
| CY1125427T1 (el) | Anti-gm-csf αντισωματα και χρησεις αυτων | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| CY1119738T1 (el) | Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων | |
| CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| MX2020001080A (es) | Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante. | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| EA201890169A1 (ru) | Тау-связывающие антитела | |
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| AR104047A1 (es) | Anticuerpos anti-ceacam6 y sus usos | |
| EA201300470A1 (ru) | Антитела | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
| CL2009000567A1 (es) | Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer. | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2011008456A (es) | Anticuerpos anti-mst1r y usos de los mismos. | |
| NO20091662L (no) | Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom | |
| EA201291004A1 (ru) | Пептиды ect2 и включающие их вакцины | |
| EP2545171A4 (en) | HJURP PEPTIDES AND VACCINES COMPRISING THEM |